Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APGE Apogee Therapeutics

交易中 05-08 14:34:51 EDT

50.48

-1.74

-3.33%

最高52.23	最低49.57	成交量7.80万
今开51.33	昨收52.22	日振幅5.09%
总市值28.48亿	流通市值18.22亿	总股本5,641万
成交额400.07万	换手率0.22%	流通股本3,609万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":50.48,"timestamp":1715193264328,"preClose":52.22,"halted":0,"volume":77995,"delay":0,"floatShares":36089365,"shares":56409933,"eps":-3.358624,"marketStatus":"交易中","marketStatusCode":2,"change":-1.74,"latestTime":"05-08 14:34:51 EDT","open":51.33,"high":52.23,"low":49.57,"amount":4000737.926,"amplitude":0.050938,"askPrice":50.57,"askSize":2,"bidPrice":50.41,"bidSize":167,"shortable":3,"etf":0,"ttmEps":-3.358624,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1715198400000},"adr":0,"listingDate":1689307200000,"adjPreClose":52.22,"preHourTrading":{"tag":"盘前","latestPrice":52.22,"preClose":52.22,"latestTime":"08:20 EDT","volume":2,"amount":103,"timestamp":1715170805931},"postHourTrading":{"tag":"盘后","latestPrice":52.22,"preClose":52.22,"latestTime":"17:14 EDT","volume":5157,"amount":269265.9744,"timestamp":1715116493607},"volumeRatio":0.327589},"requestUrl":"/m/hq/s/APGE","defaultTab":"news","newsList":[{"id":"2417239460","title":"美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239460","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417239460?lang=zh_cn&edition=full","pubTime":"2024-03-06 14:48","pubTimestamp":1709707680,"startTime":"0","endTime":"0","summary":"    路透社3月6日 - 华尔街证券分析师周三调整了对 Arrivent Biopharma、Ferguson 和 Target 等几家美国上市公司的评级和目标价。要闻             * Arrivent Biopharma Inc   ：杰富瑞给予买入评级             * 弗格森  ：杰富瑞将目标价从 222 美元上调至 244 美元             * Target Corp   ：汇丰银行将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417417822","title":"BUZZ-皮肤病药物数据良好，Apogee Therapeutics 创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2417417822","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417417822?lang=zh_cn&edition=full","pubTime":"2024-03-05 22:59","pubTimestamp":1709650767,"startTime":"0","endTime":"0","summary":" (更新)    3月5日 - ** 药物开发商Apogee Therapeutics   股价上涨43%，创下59.4美元的历史新高** 公司表示，其治疗中重度特应性皮炎的主要候选药物之一 在一项早期研究中显示出疗效** 特应性皮炎通常被称为湿疹，是一种慢性疾病，会引起皮肤炎症、发红和刺激。** TD Cowen 分析师泰勒-范布伦在一份报告中写道，数据 \"超出了所有预期\"，并称这可能是一种价值十亿美元的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417492826","title":"BUZZ-皮肤病药物数据良好，Apogee Therapeutics 公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2417492826","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417492826?lang=zh_cn&edition=full","pubTime":"2024-03-05 20:08","pubTimestamp":1709640537,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月5日 - ** Apogee Therapeutics   股价盘前上涨5.4%至44美元 ** 公司称其治疗中重度特应性皮炎的一种主要候选药物(AD) 在一项早期研究中显示出疗效 ** 特应性皮炎通常被称为湿疹，是一种慢性疾病，会引起皮肤炎症、发红和刺激。 ** 研究发现，抗体药物 APG777 安全且耐受性良好 -APGE ** 与目前批准的生物疗法相比，APG777 有可能大大减少用药次数 -APGE** 公司计划在今年上半年开始 APG777 的中期研究。** 截至上一交易日收盘，公司股价年累计上涨49.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2391169949","title":"韦德布什：2024年买这些生物科技股吧","url":"https://stock-news.laohu8.com/highlight/detail?id=2391169949","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2391169949?lang=zh_cn&edition=full","pubTime":"2023-12-15 22:46","pubTimestamp":1702651602,"startTime":"0","endTime":"0","summary":"进入2024年，韦德布什认为生物技术行业早该恢复正增长了，特别是在中小型股。韦德布什在2024年的热门选择包括Ascendis Pharma、Neurocrine Biosciences和Sarepta Therapeutics。韦德布什认为，生物技术在10月份达到了最低点，随着更多的成功项目，该行业在2024年内可能会走高。韦德布什指出，尽管2023年给生物技术投资者带来了许多挑战，但估值过高并不是其中之一，资本市场仍然对生物技术公司开放。韦德布什继续认为，到2024年，这种情况将继续存在。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":-0.0808},{"period":"3month","weight":0.4171},{"period":"6month","weight":2.2781},{"period":"1year","weight":2.0718},{"period":"ytd","weight":0.869}],"compareEarnings":[{"period":"1week","weight":0.0302},{"period":"1month","weight":-0.0025},{"period":"3month","weight":0.0382},{"period":"6month","weight":0.192},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.088}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apogee Therapeutics, Inc.于2023年6月9日作为一家特拉华州公司成立，与此次发行有关，作为一家控股公司，将全资拥有Apogee Therapeutics，LLC，并间接拥有其子公司。该公司是一家生物技术公司，致力于开发用于治疗特应性皮炎、慢性阻塞性肺病及相关炎症和免疫学适应症的差异化生物制剂，这些适应症的需求尚未得到满足。该公司的抗体项目旨在克服现有疗法的局限性，针对的是成熟的作用机制，并结合先进的抗体工程来优化半衰期和其他特性。","exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apogee Therapeutics(APGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apogee Therapeutics(APGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况